Evaluation of the in vitro efficacy of novel oxazolidinone analogues against Nontuberculous mycobacteria.

Evaluation of the in vitro efficacy of novel oxazolidinone analogues against Nontuberculous mycobacteria. Jpn J Infect Dis. 2015 May 12; Authors: Zhao W, Jiang Y, Bao P, Li Y, Tang L, Zhou Y, Zhao Y Abstract Nontuberculous mycobacteria (NTM) are associated with a number of clinical diseases and only a few antitubercular agents are active. Oxazolidinones comprise a novel class of antimicrobials as inhibitors of bacterial ribosomal protein synthesis. The first oxazolidinone antibacterial agent that was approved for clinical use, linezolid, has excellent activity against part of NTM but inefficacy against others. Sy142 and sy144 are novel oxazolidinones with proved activies against Mycobacterium.tuberculosis and Staphylococcus aureus. In this work, we compared the susceptibilities of key NTM species to linezolid, sy142, and sy144. Organisms were included 21 Mycobacterium.abscessus, 31 Mycobacterium. avium ,11 Mycobacterium.chelonae,24 Mycobacterium.fortuitum,26 Mycobacterium. kansasii and 17 Mycobacterium.intracellulare. For M. kansasii, and M. fortuitum, linezolid showed excellent activity and equal MIC range was found in sy142 and sy144.For the species that linezolid was less active, sy142 and sy144 could enhance the activities or exhibited equal efficacy comparing linezolid. Especially for M. avium and M. intracellulare, the in vitro activities of sy142 were four fold higher than linezolid. These results demonstrate the potential of ...
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research